Haloperidol fails to improve survival outcomes among ICU Patients with delirium: NEJM
A new article published in The New England Journal of Medicine shows that haloperidol therapy did not result in a substantially higher percentage of days alive and out of the hospital at 90 days compared to placebo among intensive care unit (ICU) patients with delirium.
Although there is no proof of its effectiveness, haloperidol is often used to treat delirium in patients in critical care units. Therefore, Nina Andersen-Ranberg and colleagues undertook this study to evaluate the effectiveness of haloperidol, particularly in the critical care unit.
Adult patients with delirium who had been admitted to the intensive care unit (ICU) for an acute condition were randomized to receive intravenous haloperidol (2.5 mg three times a day plus 2.5 mg as needed up to a total maximum daily dose of 20 mg) or placebo in this multicenter, blinded, placebo-controlled trial. In the ICU, haloperidol or a placebo was given for the duration of the delirium and as often as necessary for recurrences. The number of days out of the hospital and surviving 90 days following randomization was the main outcome.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.